Tailored to fit: balancing over- and undertreatment in early-stage triple-negative breast cancer patients

Wang, Y.

LIST OF PUBLICATIONS

Wang Y, Dackus GMHE, Rosenberg EH, Cornelissen S, de Boo LW, Broeks A, Brugman W, Chan TWS, van Diest PJ, Hauptmann M, Ter Hoeve ND, Isaeva OI, de Jong VMT, Jóźwiak K, Kluin RJC, Kok M, Koop E, Nederlof PM, Opdam M, Schouten PC, Siesling S, van Steenis C, Voogd AC, Vreuls W, Salgado RF, Linn SC, Schmidt MK. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to *BRCA1* status. BMC Med. 2024 Jan 9;22(1):9. doi: 10.1186/s12916-023-03233-7. PMID: 38191387; PMCID: PMC10775514.

Wang Y, Broeks A, Giardiello D, Hauptmann M, Jóźwiak K, Koop EA, Opdam M, Siesling S, Sonke GS, Stathonikos N, Ter Hoeve ND, van der Wall E, van Deurzen CHM, van Diest PJ, Voogd AC, Vreuls W, Linn SC, Dackus GMHE, Schmidt MK. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer. Eur J Cancer. 2023 Dec;195:113401. doi: 10.1016/j.ejca.2023.113401. Epub 2023 Oct 30. PMID: 37925965.

de Jong VMT *, **Wang Y ***, Ter Hoeve ND, Opdam M, Stathonikos N, Jóźwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. J Clin Oncol. 2022 Jul 20;40(21):2361-2374. doi: 10.1200/JCO.21.01536. Epub 2022 Mar 30. PMID: 35353548; PMCID: PMC9287283.
** Authors contributed equally*

Wang Y, van den Broek AJ, Schmidt MK. Letter to the editor regarding: 'Association between *BRCA* mutational status and survival in patients with breast cancer: a systematic review and meta-analysis'. Breast Cancer Res Treat. 2021 Aug;188(3):821-823. doi: 10.1007/s10549-021-06289-2. Epub 2021 Jun 16. PMID: 34132937.

Not in this thesis
de Boo LW, Jóźwiak K, Ter Hoeve ND, van Diest PJ, Opdam M, **Wang Y,** Schmidt MK, de Jong V, Kleiterp S, Cornelissen S, Baars D, Koornstra RHT, Kerver ED, van Dalen T, Bins AD, Beeker A, van den Heiligenberg SM, de Jong PC, Bakker SD, Rietbroek RC, Konings IR, Blankenburgh R, Bijlsma RM, Imholz ALT, Stathonikos N, Vreuls W, Sanders J, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen E, Bart J, Willems SM, Zolota V, Wesseling

J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, van der Wall E, Siesling S, Salgado R, Dackus GMHE, Hauptmann M, Kok M, Linn SC. Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer. ESMO Open. 2024 Mar;9(3):102923. doi: 10.1016/j.esmoop.2024.102923. Epub 2024 Mar 6. PMID: 38452438; PMCID: PMC10937239.

ABOUT THE AUTHOR

Yuwei Wang was born on June 7, 1994, in Xi'an, China. She completed her high school education at Gaoxin No.1 High School in Xi'an, and in 2012 began her academic journey in Public Health at Tongji Medical College, Huazhong University of Science and Technology in Wuhan. During her Bachelor's studies, she explored different aspects of healthcare through several internships, including a trainee doctor program at United Hospital in Wuhan and an internship at the Suizhou Center for Disease Control and Prevention.

After completing her Bachelor's degree in 2017, Yuwei moved to Nijmegen, the Netherlands, to pursue a Master's degree in Biomedical Sciences at Radboud University, specializing in Epidemiology. She soon found that she enjoyed both scientific research and life in the Netherlands. Her Master's training included two research internships: one at the Department of Geriatrics at Radboud UMC, where she studied disease patterns in dementia patients under the supervision of Dr. Miriam Haaksma and Dr. René Melis, and another through a collaboration between Integraal Kankercentrum Nederland and the Belgian Cancer Registry, where she investigated survival differences in gastric cancer patients under the supervision of Dr. Rob Verhoeven. She graduated ***cum laude*** in 2019, and these experiences strengthened her interest in epidemiology and encouraged her to stay in the Netherlands for a PhD.

Later in 2019, Yuwei joined the Netherlands Cancer Institute as a PhD candidate in the group of Prof. Dr. Marjanka Schmidt, where she spent five rewarding and memorable years. Her doctoral research focused on improving risk classification for patients with early-stage triple-negative breast cancer. During her PhD, she worked closely with colleagues from various disciplines and countries, presented her work at national and international conferences such as ESMO Breast, and published her findings in scientific journals including the *Journal of Clinical Oncology*.

Yuwei is currently working as a Postdoctoral Statistician at Johnson & Johnson Innovative Medicine in the Netherlands, where she focuses on federated data analysis in multiple myeloma patients. She continues to enjoy research and looks forward to contributing to data-driven improvements in healthcare.

ACKNOWLEDGEMENTS

It has been a long and meaningful journey from the time I arrived in the Netherlands for my master's studies to the completion of this PhD thesis. I am sincerely grateful to everyone who supported and encouraged me throughout these years. This work would not have been possible without you.

I would like to thank Prof. Marjanka Schmidt for giving me the opportunity to carry out this PhD project. Your guidance, patience, and trust allowed me the space to develop as an independent researcher. I am equally grateful to Prof. Sabine Linn for sharing your clinical knowledge and perspective, which helped me understand the medical relevance behind our research in a much deeper way.

To my office and group members, thank you for creating such a pleasant and supportive working environment. Daniele, Anna, Iris, and Maria, you welcomed me warmly when I joined the team and offered guidance during the early and often challenging stages of my PhD. The time we worked together through the COVID years, and the effort we made to stay connected, is something I will always remember. A special thanks to Daniele, who patiently helped me with statistical questions all the time and with whom I shared many discussions—not only about research, but also about life outside the office. Ann, Felipe, and Lot, as we started our PhDs around the same period, I appreciated the many discussions we had on methods and manuscripts, and the way we learned from each other. Mehrnoosh and Liz, thank you for your company and support during the final phase of my PhD; your presence made the long days in the office much easier. And to other colleagues in the group—Miriam, Renske, Susanne, Sander, Sten, Renée, Lisanne, Ellen, Emma, and Rosa—thank you for the many enjoyable lunch breaks and your support over the years. I would also like to thank my colleagues in C2 for the little chats at the coffee machine, around the lunch table, and at Friday borrels. A special thanks to Stefan for all the help and advice while I was finalizing my thesis. I would further like to thank Ellen, Suzanne, and Rosalinda for their dedicated work as office managers, particularly in coordinating meetings and securing meeting rooms for us.

To my family, thank you for your constant support. Freek, thank you for being by my side throughout this entire period—from Nijmegen to Amsterdam, through each move and each new stage of life. I am grateful for your patience, encouragement, and the stability you bring. 爸妈，感谢你们一直以来的无条件支持和信任。无论是我出国读书还是选择留在荷兰工作，你们从不过多干预我的决定，让我能够真正按照自己的想法走下去。正因为有你们的支持，我才能心无旁骛地走到今天（*Mom and Dad, thank you for your unconditional support and trust. Whether I chose to study abroad or stay in the Netherlands*

for work, you never interfered with my decisions, allowing me to follow my own path. It is because of your support that I have been able to reach this point with peace of mind).

To my Dutch family—Myriam, Chris, Yvonne, Jan, and Kanchana—thank you for welcoming me and for making the Netherlands feel like home. Your warmth and care have meant a great deal to me.

I am also grateful to Miriam, my master's supervisor and friend. Thank you for your consideration during my internship, for encouraging me at every step, and for recommending me for this PhD position. I feel truly fortunate that we became friends after my internship, and I am grateful for your ongoing support. Yuehan, thank you for the memories we shared during your time in the Netherlands and for the many conversations we still have despite the distance. I hope to visit you in the United States one day, and I also hope we will meet again in Europe.

To all collaborators and colleagues, thank you for your input, discussions, and contributions. Many of you provided feedback, data, or expertise that strengthened this work, even if your names are not listed individually here. I am also grateful to the patients whose data made this research possible; your contributions are at the foundation of scientific progress.

There are many more people I would have liked to mention, and I hope you know how much I appreciate your support and kindness. I look forward to thanking you in person as I celebrate this milestone.